Zacks Research Has Positive Estimate for BDX Q1 Earnings

Becton, Dickinson and Company (NYSE:BDX) – Equities researchers at Zacks Research upped their Q1 2025 earnings estimates for shares of Becton, Dickinson and Company in a research report issued to clients and investors on Thursday, November 28th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings per share of $2.96 for the quarter, up from their prior forecast of $2.92. The consensus estimate for Becton, Dickinson and Company’s current full-year earnings is $14.43 per share. Zacks Research also issued estimates for Becton, Dickinson and Company’s Q2 2025 earnings at $3.45 EPS, Q3 2025 earnings at $3.73 EPS, Q4 2025 earnings at $4.29 EPS, FY2025 earnings at $14.43 EPS, Q1 2026 earnings at $3.18 EPS, Q2 2026 earnings at $3.84 EPS, Q3 2026 earnings at $4.02 EPS, Q4 2026 earnings at $4.52 EPS, FY2026 earnings at $15.57 EPS and FY2027 earnings at $16.75 EPS.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business earned $3.42 EPS. The company’s revenue was up 6.9% compared to the same quarter last year.

Several other research analysts have also issued reports on BDX. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their price target for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $283.00.

Becton, Dickinson and Company Stock Down 0.7 %

Becton, Dickinson and Company stock opened at $221.26 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $249.89. The firm has a 50 day moving average price of $233.60 and a two-hundred day moving average price of $233.89. The firm has a market cap of $63.97 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 1.66 and a beta of 0.41.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be given a dividend of $1.04 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. This represents a $4.16 annualized dividend and a dividend yield of 1.88%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 63.97%.

Institutional Trading of Becton, Dickinson and Company

Several hedge funds have recently bought and sold shares of BDX. Cetera Investment Advisers grew its position in Becton, Dickinson and Company by 380.8% in the 1st quarter. Cetera Investment Advisers now owns 58,923 shares of the medical instruments supplier’s stock valued at $14,580,000 after purchasing an additional 46,668 shares during the period. Cetera Advisors LLC boosted its holdings in Becton, Dickinson and Company by 8.1% during the 1st quarter. Cetera Advisors LLC now owns 11,998 shares of the medical instruments supplier’s stock worth $2,969,000 after acquiring an additional 896 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Becton, Dickinson and Company by 132.2% during the 2nd quarter. GAMMA Investing LLC now owns 1,883 shares of the medical instruments supplier’s stock worth $440,000 after acquiring an additional 1,072 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in Becton, Dickinson and Company by 56.2% during the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 603 shares of the medical instruments supplier’s stock worth $141,000 after acquiring an additional 217 shares during the last quarter. Finally, Douglas Lane & Associates LLC boosted its holdings in Becton, Dickinson and Company by 11.6% during the 2nd quarter. Douglas Lane & Associates LLC now owns 1,745 shares of the medical instruments supplier’s stock worth $408,000 after acquiring an additional 182 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.